Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18304150 | 0.86 | PDE10A (0.33) | RAB9APKMNPC1SMN1; SMN2KDM4E | |
| SCHEMBL29020708 | 0.82 | RAB9A (0.33) | RAB9APKMNPC1SMN1; SMN2KDM4E | |
| SCHEMBL20533689 | 0.74 | KDM4E (0.43) | SMN1; SMN2KDM4ETSHRRXFP1 | |
| SCHEMBL9598573 | 0.73 | PIK3CG (0.55) | MCHR1RAB9APKMNPC1SMN1; SMN2 | |
| SCHEMBL15655042 | 0.72 | HDAC1 (0.32) | RAB9ANPC1 | |
| SCHEMBL1302277 | 0.72 | PIK3CG (0.53) | — | |
| SCHEMBL10069308 | 0.71 | NOTUM (0.33) | KDM4E | |
| SCHEMBL29019469 | 0.70 | PTGS1 (0.47) | RAB9ANPC1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL9936358 | 0.69 | PIK3R1 (0.32) | — | |
| SCHEMBL17466611 | 0.69 | DRD2 (0.47) | MCHR1RAB9ANPC1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | UCB S.A. (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MCHR1 3657/4885RAB9A 1597/4885PKM 1289/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | MCHR1 3507/4885RAB9A 1594/4885PKM 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.